The FDA has approved VIZZ, the first aceclidine-based eye drop to treat presbyopia, offering 10-hour near vision improvement without harming distance vision.
Say Goodbye to Eyeglasses and Contact Lenses
United States — Agencies
The U.S. Food and Drug Administration (FDA) has officially approved VIZZ (aceclidine ophthalmic solution) 1.44%—the first and only aceclidine-based eye drop designed to treat age-related blurry near vision (presbyopia) in adults 1.
Lenz Therapeutics, the developer, is preparing to roll out clinic samples as early as October 2025, with the full-scale U.S. commercial launch expected by mid-fourth quarter 2025 2.
Presbyopia is an age-related condition in which the crystalline lens of the eye gradually loses its flexibility, impairing one’s ability to focus on close objects. This progressive condition, common in those over age 45, typically prompts reliance on reading glasses or multifocal lenses. Adults over 50 may lose approximately 1.5 lines of near vision every six years 3.
Enter VIZZ, a novel once-daily, preservative-free eye drop solution that may replace—or at least significantly reduce reliance on—corrective eyewear for near vision.
Active ingredient: Aceclidine, a cholinergic muscarinic receptor agonist, previously used for glaucoma treatment in Europe under the name Glaucostat. This marks its first FDA approval in the U.S. for presbyopia 4.
Mechanism: VIZZ acts as a pupil-selective miotic agent, primarily contracting the iris sphincter muscle with minimal ciliary muscle stimulation. This creates a pinhole effect—narrowing the pupil to under 2 mm—and thereby dramatically increases the eye’s depth of focus, improving near vision without inducing a myopic shift 5.
The FDA’s approval is based on robust data from three Phase 3, randomized, double-masked, controlled studies—CLARITY 1, CLARITY 2, and CLARITY 3 6:
CLARITY 1 & 2: Included 466 adult participants, receiving once-daily VIZZ for 42 days.
CLARITY 3: Enrolled 217 participants over a 6-month daily dosing period to confirm long-term safety.
Across all trials, there were over 30,000 treatment days, with no serious treatment-related adverse events observed 9.
According to prescribing data and trial outcomes:
Most common side effects (generally mild and transient):
Warnings & Precautions (from prescribing information):
Market rollout:
Healthcare Impact:
Expert Perspective:
VIZZ (aceclidine 1.44%) stands to transform the landscape of presbyopia treatment in the U.S.—offering a first-of-its-kind, once-daily, non-invasive therapy for near vision impairment:
Patients and eye-care professionals seeking a modern, flexible alternative to reading glasses should consider VIZZ, pending consultation and medical eligibility.
Comprehensive 2025 review of Zyn nicotine pouches—covering user experiences, health risks, regulatory updates, and how Zyn stacks up against competitors.
Read more →
Explore the latest data on Zyn nicotine pouches in 2025—covering their safety, health impacts, user reviews, regulatory status, and risks, especially for youth and children.
Read more →